DeepMed Research

Medical University of Vienna

🇦🇹Austria

Country: 🇦🇹Austria

Ownership: Private

Established: 1365-01-01

Employees: 1K

Market Cap: -

Website: http://www.meduniwien.ac.at

Clinical Trials

Predicting Lung Cancer-Associated Cachexia With PET Imaging

Not Applicable

Recruiting

Conditions: Cachexia
Lung Neoplasm

Interventions: Other: Stress Reduction Training

First Posted Date: 2023-06-22

Last Posted Date: 2023-06-27

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 150

Registration Number: NCT05912465

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria
🇮🇹
AOUC Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
🇩🇪
University of Leipzig Medical Center, Leipzig, Germany

Health Status of Patients After Surgically Implanted Biological and TAVI: a Population-based Retrospective Analysis

Completed

Conditions: Aortic Valve Disease

Interventions: Device: Aortic Valve Replacement

First Posted Date: 2023-06-22

Last Posted Date: 2023-06-22

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 18882

Registration Number: NCT05912660

Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation

Not Applicable

Recruiting

Conditions: Congenital Heart Disease
Airway Complication of Anesthesia

Interventions: Device: laryngoscopy

First Posted Date: 2023-06-13

Last Posted Date: 2024-07-12

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 180

Registration Number: NCT05902013

Locations: 🇦🇹
Medical University Vienna, Vienna, Austria

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Phase 2

Recruiting

Conditions: Mantle-cell Lymphoma

Interventions: Drug: Polatuzumab, bendamustin und rituximab

First Posted Date: 2023-05-22

Last Posted Date: 2024-05-29

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 16

Registration Number: NCT05868395

Locations: 🇦🇹
AKH Vienna, Division of Oncology Department of Medicine I, Vienna, Austria

Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

Phase 2

Recruiting

Conditions: Breast Cancer Stage IV

Interventions: Drug: Datopotamab deruxtecan

First Posted Date: 2023-05-19

Last Posted Date: 2023-10-19

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 20

Registration Number: NCT05866432

Locations: 🇦🇹
AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology, Vienna, Austria

BCC Excision Revisited

Completed

Conditions: Eye Cancer
Eye Diseases
Basal Cell Carcinoma

First Posted Date: 2023-05-10

Last Posted Date: 2023-05-16

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 451

Registration Number: NCT05853315

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Corneal Findings in Patients Treated With Belantamab Mafodotin

Terminated

Conditions: Corneal Cyst
Multiple Myeloma
Corneal Diseases

First Posted Date: 2023-04-27

Last Posted Date: 2025-05-08

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 12

Registration Number: NCT05833737

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Metacognitive Training in Ultra-high Risk

Not Applicable

Recruiting

Conditions: Clinical High Risk for Psychosis
At-risk Mental State
Ultra-high Risk for Psychosis

Interventions: Behavioral: Metacognitive Training

First Posted Date: 2023-04-25

Last Posted Date: 2024-03-15

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 30

Registration Number: NCT05827900

Locations: 🇦🇹
Department of Psychiatry and Psychotherapy, Vienna, Austria
🇦🇹
Department of Child and Adolescent Psychiatry, Vienna, Austria

Intraindividual Comparison of EMO IOLs

Not Applicable

Recruiting

Conditions: Age Related Cataracts

Interventions: Procedure: phacoemulsification and intraocular lens implantation

First Posted Date: 2023-04-20

Last Posted Date: 2024-12-19

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 311

Registration Number: NCT05822089

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Multicentric Prospective T1 Urinary Bladder Cancer Registry

Recruiting

Conditions: T1 Urinary Bladder Cancer

First Posted Date: 2023-03-30

Last Posted Date: 2023-04-04

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 700

Registration Number: NCT05792033

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy